{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T19:05:06Z","timestamp":1779563106731,"version":"3.53.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mavacamten is a first-in-class cardiac myosin inhibitor (CMI) that reduces left ventricular outflow tract (LVOT) obstruction in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, excessive myosin inhibition may cause significant systolic dysfunction and rarely requires intensive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 40-year-old woman with obstructive HCM presented with dyspnoea and palpitations. Mavacamten 5\u2005mg daily improved symptoms after an inadequate response to \u03b2-blocker therapy, although significant LVOT obstruction persisted. Following dose escalation to 10\u2005mg daily, her condition rapidly deteriorated, and she developed cardiogenic shock with severe biventricular systolic dysfunction and atrial fibrillation (AF) with a rapid ventricular response. Further history revealed recent alcohol consumption before the symptom exacerbation. She was admitted to the intensive care unit, mavacamten was discontinued, and intravenous amiodarone was initiated. Given the persistent haemodynamic instability and recent anticoagulation interruption, transoesophageal echocardiography was performed, identifying a large left atrial thrombus and precluding cardioversion. With therapeutic anticoagulation, rate control, and supportive care, sinus rhythm was spontaneously restored, and the left ventricular ejection fraction recovered to 50% within 5 days. At follow-up, systolic function had fully normalised. Low-dose mavacamten and \u03b2-blocker therapy were cautiously reintroduced, with reinforced counselling on alcohol abstinence and anticoagulation adherence. The patient remains clinically stable without recurrent ventricular dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case highlights that acute biventricular dysfunction may occur abruptly after CMI dose escalation, particularly when complicated by AF. Early recognition, prompt drug discontinuation, careful monitoring, and comprehensive patient education are essential for the safe clinical use of CMIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytag348","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:43:58Z","timestamp":1778240638000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiogenic shock and atrial fibrillation after mavacamten dose escalation in obstructive hypertrophic cardiomyopathy: a case report"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2602-0626","authenticated-orcid":false,"given":"Woo Jae","family":"Jeong","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine , 170 Juhwa-ro, Ilsanseo-gu, Goyang-si, Gyeonggi-do 10380 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-5217","authenticated-orcid":false,"given":"Sung Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine , 170 Juhwa-ro, Ilsanseo-gu, Goyang-si, Gyeonggi-do 10380 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-817X","authenticated-orcid":false,"given":"Sung Woo","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine , 170 Juhwa-ro, Ilsanseo-gu, Goyang-si, Gyeonggi-do 10380 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-9931","authenticated-orcid":false,"given":"June","family":"Namgung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine , 170 Juhwa-ro, Ilsanseo-gu, Goyang-si, Gyeonggi-do 10380 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-7651","authenticated-orcid":false,"given":"Kyu-Yong","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026052314563643800_ytag348-B1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"2026052314563643800_ytag348-B2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2026052314563643800_ytag348-B3","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026052314563643800_ytag348-B4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026052314563643800_ytag348-B5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026052314563643800_ytag348-B6","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.123.066916","article-title":"Pharmacogenetic influences over mavacamten pharmacokinetics: considerations for the treatment of individuals with hypertrophic cardiomyopathy","volume":"149","author":"McGurk","year":"2024","journal-title":"Circulation"},{"key":"2026052314563643800_ytag348-B7","doi-asserted-by":"crossref","first-page":"ytaf490","DOI":"10.1093\/ehjcr\/ytaf490","article-title":"Catastrophic apical ballooning in an obstructive hypertrophic cardiomyopathy patient treated with mavacamten: case report","volume":"9","author":"De Roeck","year":"2025","journal-title":"Eur Heart J Case Rep"},{"key":"2026052314563643800_ytag348-B8","doi-asserted-by":"crossref","first-page":"105277","DOI":"10.1016\/j.jaccas.2025.105277","article-title":"Cardiogenic shock in hypertrophic cardiomyopathy treated with mavacamten and clarithromycin","volume":"30","author":"Alabdaljabar","year":"2025","journal-title":"JACC Case Rep"},{"key":"2026052314563643800_ytag348-B9","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.jacadv.2024.101210","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy","volume":"3","author":"Weissler-Snir","year":"2024","journal-title":"JACC Adv"},{"key":"2026052314563643800_ytag348-B10","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026052314563643800_ytag348-B11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00228-025-03991-8","article-title":"CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy","volume":"82","author":"Kasolo","year":"2026","journal-title":"Eur J Clin Pharmacol"},{"key":"2026052314563643800_ytag348-B12","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM199609263351305","article-title":"The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy","volume":"335","author":"Paz","year":"1996","journal-title":"N Engl J Med"},{"key":"2026052314563643800_ytag348-B13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2010.08.641","article-title":"Alcohol consumption and risk of atrial fibrillation: a meta-analysis","volume":"57","author":"Kodama","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytag348\/68268701\/ytag348.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/5\/ytag348\/68268701\/ytag348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/5\/ytag348\/68268701\/ytag348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T18:56:48Z","timestamp":1779562608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytag348\/8675963"}},"subtitle":[],"editor":[{"given":"Emmanouil","family":"Androulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Enrico","family":"Bonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Elvis J","family":"Amao-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Tijn Julian Pieter","family":"Heeringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytag348","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,30]]},"article-number":"ytag348"}}